Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$41.84 USD
+0.74 (1.80%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $41.87 +0.03 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
IONS 41.84 +0.74(1.80%)
Will IONS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for IONS
Ionis to hold first quarter 2024 financial results webcast
Hepion ends Phase 2 study for NASH drug due to cash restraints
ClearBridge Multi Cap Growth Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary
Wolfe upgrades Ionis to outperform, cites upcoming catalysts